NYSE:NUVBPharmaceuticals
Nuvation Bio (NUVB) Expands Global Taletrectinib Rights With Eisai Collaboration And Licensing Deal
In early January 2026, Nuvation Bio Inc. and Eisai Co. Ltd. announced an exclusive license and collaboration agreement granting Eisai rights to develop, register and commercialize taletrectinib (IBTROZI) for ROS1-positive non-small cell lung cancer across Europe, large parts of Asia-Pacific, the Middle East, North Africa, Russia, Turkey, Canada, Australia, New Zealand and India, in return for an upfront payment of €50 million (about US$60 million), up to €145 million (about US$170 million)...